CD47 Targeting Therapeutics Market Forecast Predicts Exponential Revenue Surge Amid Rising Adoption of Targeted Cancer Treatments

Insight Analytics Pvt. Ltd. announces the release of a market assessment report on the "Global CD47 Targeting Therapeutics Market- by Target Disease Indication (Acute Myeloid Leukemia, Non-Hodgkin Lymphoma, Colorectal Cancer, Diffuse Large B-cell Lymphoma, Myelodysplastic Syndromes, Non-Small Cell Lung Cancers, Ovarian Epithelial Cancer, Oral mucositis, Small Cell Lung Cancers and Other Diseases Indications), Type of Molecule (Biologics and Small Molecule), Trends, Industry Competition Analysis, Revenue and Forecast To 2030."

Request for Sample Pages: https://www.insightaceanalytic.com/request-sample/1290

According to the latest research by Insight Analytics, the global CD47 Targeting Therapeutics market is expected to grow with a CAGR of 62.0 % during a forecast period of 2023-2031.

CD47 is a transmembrane protein that plays a crucial role in promoting cancer cell survival across various cancer types by undergoing glycosylation on the surface of malignant cells. Its interaction with signal-regulatory protein alpha (SIRPα) triggers an inhibitory signaling cascade that suppresses macrophage-mediated phagocytosis of tumor cells. Consequently, therapeutic strategies aimed at blocking the CD47-SIRPα axis have the potential to enhance immune-mediated clearance of cancer cells by facilitating macrophage phagocytosis.

Several factors are contributing to the growth of the global CD47 targeting therapeutics market. These include the increasing application of CD47-targeted therapies in oncology, a growing aging population, a high incidence of various cancers, and heightened public awareness regarding the benefits of these treatment modalities. Additionally, expanded investment in research and development to deepen scientific understanding of CD47-related signaling pathways is expected to present new opportunities for market advancement. This improved knowledge base may enable the development of innovative anti-cancer therapies focused on inhibiting CD47 signaling mechanisms.

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-04

However, market growth may face constraints during the forecast period due to several challenges. These include the high production costs and complexities associated with the manufacturing of targeted therapies, potential off-target effects that may damage healthy cells, and stringent regulatory requirements surrounding therapeutic approvals.

Regionally, North America is projected to maintain a significant share of the CD47 targeting therapeutics market over the coming years. This growth is attributed to the region's increasing cancer incidence and mortality rates, as well as its strong adoption of advanced therapeutic technologies and treatment approaches. The United States, in particular, plays a pivotal role in driving R&D initiatives related to CD47-targeted drug development.

The Asia-Pacific region is also expected to witness substantial market expansion throughout the forecast period. Contributing factors include the growing adoption of CD47-targeted therapies, a rapidly aging population, high prevalence of cancer, and rising awareness of the therapeutic benefits of targeting CD47 pathways within the region.

Major market players operating in the CD47 Targeting Therapeutics market include
Conjupro biotherapeutics (US), EpicentRx (US), Forty Seven (US), ImmuneOncia Therapeutics (Korea), ImmuneOnco Biopharmaceuticals (China), Innovent Biologics (China), KAHR Medical (Israel), TG Therapeutics, Adagene, Alector, Inc., Apmonia Therapeutics, I-MAB Biopharma Co., Ltd., Light Chain Bioscience (Switzerland), Morphiex (US), Trillium Therapeutics (Canada), QLSF Biotherapeutics Inc., Phanes Therapeutics, Inc., Bio-Thera Solutions, others.

Recent collaborations and agreements in the market:
• In January 2022, the next-generation CD47 blocker evorpacept, manufactured by ALX Oncology, was accorded orphan drug designation ("ODD") for treating patients with gastroesophageal junction and gastric cancer.
• In September 2021, for US$2.3 billion, Pfizer Inc. (US) purchased Trillium Therapeutics Inc. (Canada), which had CD47 prospects. Pfizer now has a stronger cancer and hematology portfolio thanks to this acquisition.
• In June 2021, to test the efficacy of combining ALX148, a next-generation CD47 blocker, and CYRAMZA (ramucirumab), Lilly's anti-VEGFR2 antibody, for the treatment of gastric cancer, ALX Oncology (US) and Eli Lilly and Company (US) agreed into a clinical study partnership and supply agreement.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/1290

Market Segments
Global CD47 Targeting Therapeutics Market, by Target Disease Indication, 2022-2030 (Value US$ Mn)
• Acute Myeloid Leukemia
• Non-Hodgkin Lymphoma
• Colorectal Cancer
• Diffuse Large B-cell Lymphoma
• Myelodysplastic Syndromes
• Non-Small Cell Lung Cancers
• Ovarian Epithelial Cancer
• Oral mucositis
• Small Cell Lung Cancers
• Other Diseases Indications
Global CD47 Targeting Therapeutics Market, by Type of Molecule, 2022-2030 (Value US$ Mn)
• Biologics
• Small Molecule
Global CD47 Targeting Therapeutics Market, by Region, 2022-2030 (Value US$ Mn)
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa
North America CD47 Targeting Therapeutics Market, by Country, 2022-2030 (Value US$ Mn)
• U.S.
• Canada
Europe CD47 Targeting Therapeutics Market, by Country, 2022-2030 (Value US$ Mn)
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe
Asia Pacific CD47 Targeting Therapeutics Market, by Country, 2022-2030 (Value US$ Mn)
• India
• China
• Japan
• South Korea
• Australia & New Zealand
Latin America CD47 Targeting Therapeutics Market, by Country, 2022-2030 (Value US$ Mn)
• Brazil
• Mexico
• Rest of Latin America
Middle East & Africa CD47 Targeting Therapeutics Market, by Country, 2022-2030 (Value US$ Mn)
• GCC Countries
• South Africa
o Rest of Middle East & Africa

Why should buy this report:
 To receive a comprehensive analysis of the prospects for the global CD47 Targeting Therapeutics market
 To receive an industry overview and future trends in the CD47 Targeting Therapeutics market
 To analyze the CD47 Targeting Therapeutics market drivers and challenges
 To get information on the CD47 Targeting Therapeutics market value (US$Mn) forecast to 2030
 Significant investments, mergers & acquisitions in the CD47 Targeting Therapeutics market industry

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.